The A3 adenosine receptor, A3AR, belongs to the family of Gi proteins, which upon induction, suppresses the formation of cAMP and its downstream eectors. Recent studies have indicated that activation of A3AR by its agonist, IB-MECA, results in growth inhibition of malignant cells. Here we demonstrate the ability of IB-MECA to decrease the levels of protein kinase A, a downstream eector of cAMP, and protein kinase B/Akt in melanoma cells. Examination of glycogen synthase kinase 3b, GSK-3b, whose phosphorylation is controlled by protein kinase A and B, showed a substantial decrease in the levels of its phosphorylated form and an increase in total GSK-3b levels in IB-MECA treated melanoma cells. This observation suggests that the treatment of cells with IB-MECA augments the activity of GSK-3b in the cells. Evaluation of b-catenin, a key component of Wnt signaling pathway which, upon phosphorylation by GSK-3b rapidly ubiquitinates, showed a substantial decrease in its level after IB-MECA treatment. Accordingly, the level of b-catenin responsive cell growth regulatory genes including c-myc and cyclin D1 was severely declined upon treatment of the cells with IB-MECA. These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3b and b-catenin in the anti-tumor activity of A3AR agonists.
Introduction
Adenosine binds to A1, A2 a , A2 b , and A3 G proteinassociated receptors and induces a series of signaling pathways that control several biological events (Linden, 1991; Stiles, 1990) . Results from recent studies illustrated that adenosine has the ability to inhibit the proliferation of various tumor cells, including melanoma Fishman et al., 1998) . Pharmacological studies utilizing antagonists to the various adenosine receptors revealed that A3AR plays a key role in the adenosine-induced inhibition of tumor cell proliferation . These observations provided a rationale for examining the anti-cancer activity of synthetic agonists to A3AR, a Gi protein coupled receptor. In this respect, our early eorts showed that the A3AR agonists, 1-Deoxy-1- [6 -[[(3-iodophenyl) methyl]amino]-9H-purine-9-y1]-Nmethyl-b-D-ribofuranuronamide (IB-MECA) and its 2-chloro derivative, Cl-IB-MECA, have the ability to inhibit the growth of B16-F10 melanoma cells through cell cycle arrest in the G0/G1 phase. Moreover, these compounds suppressed tumor cell growth in vivo when administered to mice inoculated with the B16-F10 melanoma cells .
Activation of A3AR is known to inhibit adenylyl cyclase activity and cAMP formation (Zhao et al., 2000) . cAMP modulates the level and activity of protein kinase A, PKA, and protein kinase B, PKB/ Akt, both of which play a central role in modulation of a variety of extracellular signals (Filippa et al., 1999; Sable et al., 1997) . PKA contains a catalytic subunit, PKAc, which dissociates from the parent molecule upon activation with cAMP. Recent studies have demonstrated that PKAc phosphorylates and inactivates glycogen synthase kinase 3b (GSK-3b), a serine/ threonine kinase that regulates glycogen synthesis in response to various stimuli (Fang et al., 2000) . GSK-3b also serves as a direct substrate of PKB/Akt that induces its phosphorylation and inactivation (Cross et al., 1995) . GSK-3b acts as a key element in the Wnt signaling pathway by dictating cell fate during embryogenesis and tumorigenesis. In its active form, GSK-3b suppresses mammalian cell proliferation and survival by phosphorylating the cytoplasmic protein, bcatenin. The phosphorylated form of b-catenin became the target for degradation by the ubiquitin pathway. Upon phosphorylation, GSK-3b loses its ability to Oncogene (2002) 21, 4060 ± 4064 modify b-catenin, hence, this protein accumulates in the cytoplasm and subsequently translocates to the nucleus where it associates with LEF/TCF to induce transcription of cyclin D1 and c-myc (Ferkey and Kimelman, 2000; Novak and Dedhar, 1999; Morin, 1999) . Earlier studies suggested the involvement of the Wnt signaling pathway in the pathogenesis of malignant melanoma (Bonvini et al., 2000; Robbins et al., 1996) .
In this study, we demonstrate that activation of A3AR in melanoma cells decreases cAMP, thereby preventing the activation of both PKA and PKB/Akt. This event diminishes phosphorylation of GSK-3b and by maintaining this protein in its active form, leads to inhibition of cell proliferation via the Wnt pathway.
In the ®rst series of experiments we examined the eect of the A3AR agonist, IB-MECA, on the proliferation of the melanoma cell line, B16-F10 by [ 3 H]thymidine incorporation assay. As shown in Figure  1 , increasing concentrations of IB-MECA in the media results in a decrease in the growth of B16-F10 cells. Of note, while no evidence for apoptosis was obtained at these concentrations, treatment of cells with IB-MECA at the higher concentrations, i.e. 100 mM, caused apoptosis in these cells (data not shown). The antagonist to A3AR, MRS 1523, was able to block anti-proliferative activity of IB-MECA, suggesting that the observed tumor growth inhibition is mediated through A3AR. To investigate the mechanism whereby IB-MECA causes cell growth inhibition, we focused our attention on the signaling pathway downstream to A3AR. As activation of A3AR decreases the production of cAMP, we determined the level of cAMP in the control and IB-MECA treated cells by ELISA. Our results showed a marked decrease in the level of cAMP in IB-MECA treated cells (0.5+0.041 pg/ml) compared to the control cells (4.2+0.31 pg/ml) verifying the ability of IB-MECA to aect adenylyl cyclase activity. Examination of PKA, whose expression and activity is regulated by cAMP, revealed that at 10 and 20 min after serum stimulation, treatment of the cells with IB-MECA signi®cantly decreased the level of PKA in B16-F10 cells ( Since GSK-3b, a component of the Wnt signaling pathway presents one potential target for PKA and PKB/Akt (Li et al., 2000; Moule, 1997) , in the next series of experiments we examined the level of GSK-3b by Western blot technique. As shown in Figure 3 (Ausubel et al., 1989) . Approximately 50 mg of protein were analysed by Western blot using rabbit polyclonal antibodies that recognize PKAc and b-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The arrow points to the position of a band corresponding to PKAc. (Figure 3a, middle) . As phosphorylation of GSK-3b by PKB/Akt results in inactivation of this protein, we examined the level of the phosphorylated form of GSK-3b in the control and IB-MECA treated cells. Our results showed a noticeable decrease in the level of phosphorylated GSK-3b in IB-MECA treated cells (Figure 3a , bottom). We also investigated the level of GSK-3b by immunocytochemistry using anti-GSK3b antibody. As illustrated in Figure 3b , treatment of the cells with IB-MECA caused a noticeable decrease in the number of cells (top panels) and a signi®cant enhancement in the amount of GSK-3b in the cells (bottom panels). As before, the antagonist to A3AR was able to reverse the negative eect of IB-MECA upon PKA expression and decreased the elevated level of GSK-3b, which was seen upon IB-MECA treatment (data not shown). These observations further verify that the modulation of PKA and GSK-3b is mediated by A3AR.
In light of these results, in the next series of experiments we examined the level of b-catenin, the well-known substrate of GSK-3b upon treatment of cells with IB-MECA. Results from Western blot analysis revealed a drastic decrease in the level of bcatenin upon treatment of the cells with IB-MECA (Figure 4a) . Again, the level of b-actin remained unchanged. Evaluation of b-catenin by immunohistochemistry indicated strong staining of b-catenin in the control cells and very weak staining in the cells treated with IB-MECA. These observations demonstrate that treatment of cells with IB-MECA decreases the level of b-catenin in the cells. The observed reduced level of bcatenin in the IB-MECA treated cells may be due to the rapid ubiquitination of this protein by GSK-3b (Novak and Dedhar, 1999) , whose level is increased in IB-MECA treated cells.
As stated earlier, the stability of b-catenin in cells results in its nuclear import through its partnership (Gan et al., 2001) with LEF/TCF where it stimulates expression of genes such as cyclin D1 and c-myc. This event can eventually lead to uncontrolled cell growth and proliferation (Ferkey and Kimelman, 2000) . The reduced level of b-catenin in IB-MECA treated cells prompted us to investigate the level of c-myc and cyclin D1 by Western blot analysis. As shown in Figure 5 , the intensity of the band corresponding to c-myc and cyclin D1 was signi®cantly less in cells treated with IB-MECA, suggesting down-regulation of c-myc and cyclin D1 by IB-MECA in melanoma cells. As before, this eect is speci®c for c-myc and cyclin D1, as the level of bactin remains unchanged upon treatment. Furthermore, the observed inhibition by IB-MECA is at the transcription level as our results from RNase Protection Assay showed a similar decline in the level of transcript corresponding to cyclin D1 and cyclin D2, but not cyclin A2, cyclin B2, and cyclin D3 upon IB-MECA treatment (Figure 5c ).
In this study, we identi®ed a potential mechanism which mediates suppression of melanoma cell growth by A3AR agonist, IB-MECA. The Wnt signaling pathway which is highly active during embryogenesis through modulation of several key cell cycle proteins, plays an important role in the development of various tumors (McEwen and Peifer, 2000) . In a number of neoplastic cells including malignant melanoma, the central protein of this pathway, GSK-3b, loses its ability to phosphorylate b-catenin, an event that leads to ubiquitination of b-catenin in the cells (Morin, 1999; Bonvini et al., 2000; Robbins et al., 1996) . At least two eector proteins, i.e. PKB/Akt and PKA, by controlling the level of expression and activity of GSK-3b, may aect the regulatory events associated with the Wnt pathway. For example, both PKB/Akt and PKA which phosphorylate GSK-3b at serine 9 and 21 can render this protein to its inactive form (Fang et al., 2000; Cross et al., 1995; Li et al., 2000) . On the other hand, cAMP, by dissociating the PKAc unit from its parent molecule, potentiates PKA (Fang et al., 2000) . Recent studies have provided evidence suggesting that cAMP can also activate PKB/Akt (Filippa et al., 1999) , a key kinase which is commonly activated in response The interaction of IB-MECA with A3AR results in transmission of signals to PKA and PKB/Akt that results in an inhibition of GSK-3b phosphorylated form and the enhancement of its level in the cells. The elevated GSK-3b by phosphorylating b-catenin causes ubiquitination in the cytoplasm, thus, preventing its nuclear import. These events cause suppression of cyclin D1 and c-myc expression that eventually cause cell growth suppression to stimulation by various growth factors through a phosphatidylinositol 3' kinase, PI-3-kinase, dependent pathway (Moule et al., 1997) . These observations along with our results presented here provide a model which describes the potential mechanism whereby IB-MECA suppresses growth of tumor cells. According to this model, activation of A3AR by IB-MECA decreases formation of cAMP which either directly or indirectly inhibits the levels of PKA and PKB/Akt (Figure 6 ). Inhibition of PKA and PKB/Akt, in turn, results in reduced levels of the inactive form of GSK-3b, thus permitting this kinase to phosphorylate b-catenin. As phosphorylation of b-catenin results in rapid degradation of this protein, cells which are treated with IB-MECA show a reduced level of b-catenin. A decrease in the b-catenin levels in IB-MECA treated B16-F10 cells eventually leads to suppression of c-myc and cyclin D1 expression, genes whose transcription can be augmented upon nuclear import of b-catenin and its partner TCF/LEF-1. In fact, earlier results demonstrated overexpression of both cyclin D1 and c-myc in melanoma cells (Caballero et al., 2001; D'Agnano et al., 2001; Miracco et al., 2000) . Down-regulation of both c-myc and cyclin D1, the two major downstream targets in the Wnt pathway which controls cell proliferation, upon IB-MECA treatment is consistent with the involvement of the Wnt pathway in IB-MECA mediated suppression of tumor cell growth. It is also important to note that GSK-3b, c-myc PKA, and PKB/Akt may also act through alternative pathways to exert the cytostatic eect upon tumor cells. Earlier reports indicated that GSK-3b directly phosphorylates cyclin D1 on thr 286 which triggers its rapid turnover (Diehl et al., 1998) . Thus it is likely that IB-MECA, by altering the state of cyclin D1 phosphorylation reduces the level of this protein in the cells. The decrease in the level of c-myc may also in¯uence telomerase activity in the cells as earlier studies pointed to reactivation and stabilization of telomerase upon c-myc overexpression (Cerni, 2000) . In support of this notion our previous results demonstrated that treatment of B16-F10 cells with IB-MECA reduces the telomerase activity in the cells . Experiments are in progress to investigate the eect of IB-MECA on deregulation of other important biological pathways which are involved in the control of cell proliferation.
